2013 Clinical Trials Conditions Programs 
Cannabis Law Report
FEBRUARY 24, 2022
Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions. In 2013, section C and J of Canada’s FDR statute were amended so that “restricted drugs” were inaccessible through SAP.
Canna Law Blog
NOVEMBER 27, 2021
Notwithstanding its dubious distinction as a Schedule I drug, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. regulators to launch a clinical program to study the use of DMT for the treatment of stroke-related dysfunction.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 19, 2022
After a psilocybin treatment,(it’s like) you’re still in your car, in traffic, but you have the windows up; the air conditioning is on and it’s quiet. Before January, people could only access psychedelic-assisted psychotherapy through clinical trials or medical exemptions. It’s just you and the music.”
Cannabis Law Report
MAY 29, 2022
FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. Clinical Trials and Human Subject Protections. Fast Track review is for drugs that treat serious conditions and fill an unmet medical need.
The Cannigma
JUNE 15, 2021
Charlotte’s story was featured on CNN in 2013 and millions of people saw with their own eyes how a few drops of cannabis oil succeeded where no other epilepsy treatment had —- reducing her seizures from 300 each week to less than three a month. A multi-target panacea? Easy access. CBD’s interaction with benzodiazepines.
Cannabis Law Report
JULY 25, 2022
Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. The charity was eventually instructed to pull an advertisement for the study by the ethics committee that conditionally approved the trial.
Cannabis Law Report
JANUARY 20, 2022
ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Founded in 2013, Eleusis is dedicated to transforming psychedelics into medicines. About Eleusis.
Expert insights. Personalized for you.
52 
Let's personalize your content